Details of the Drug

General Information of Drug (ID: DMDGCFC)

Drug Name

EHP-101

Synonyms

EHP-101; Etrinabdione; VCE-004.8; 1818428-24-8; KTJCIKNF3F; VCE-004; UNII-KTJCIKNF3F; EHP101; (1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-(1,1'-bi(cyclohexane))-2',3,6-triene-2,5-dione; 2,5-Cyclohexadiene-1,4-dione, 2-hydroxy-3-((1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-6-pentyl-5-((phenylmethyl)amino)-; (1'R,6'R)-3-(BENZYLAMINO)-6-HYDROXY-3'-METHYL-4-PENTYL-6'-(PROP-1-EN-2-YL)-(1,1'-BI(CYCLOHEXANE))-2',3,6-TRIENE-2,5-DIONE; (1'R,6'R)-3-(benzylamino)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione; etrinabdione [INN]; CHEMBL5095098; SCHEMBL17197618; BDBM482299; US10919843, Compound VIII; EX-A3105; ZB1584; AKOS040740523; VCE-?004.8; AC-36333; MS-27754; EHP-101 (VCE- 004.8); HY-128872; CS-0101637; (1'R,6'R)-3-(benzylamino)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)[1,1'-bi(cyclohexane)]-1(6),2',3-triene-2,5-dione; 2-Hydroxy-3-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-6-pentyl-5-[(phenylmethyl)amino]-2,5-cyclohexadiene-1,4-dione; 5-(benzylamino)-4-hydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylcyclohexa-3,5-diene-1,2-dione

Indication

Disease Entry	ICD 11	Status	REF
Systemic sclerosis	4A42	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C28H35NO3
Canonical SMILES: CCCCCC1=C(C(=C(C(=O)C1=O)C2C=C(CCC2C(=C)C)C)O)NCC3=CC=CC=C3
InChI: InChI=1S/C28H35NO3/c1-5-6-8-13-22-25(29-17-20-11-9-7-10-12-20)27(31)24(28(32)26(22)30)23-16-19(4)14-15-21(23)18(2)3/h7,9-12,16,21,23,29,31H,2,5-6,8,13-15,17H2,1,3-4H3/t21-,23+/m0/s1
InChIKey: CGGGAXJIRQSRPH-JTHBVZDNSA-N

Cross-matching ID

PubChem CID: 118465221
TTD ID: D6Z5NV

References

1	ClinicalTrials.gov (NCT04166552) A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis. U.S.National Institutes of Health.